Search / Trial NCT00000372

Glycine and D-Cycloserine in Schizophrenia

Launched by MASSACHUSETTS GENERAL HOSPITAL · Nov 2, 1999

Apply for Trial

Trial Information

Current as of June 14, 2024

Withdrawn

Keywords

Adult Amino Acids Cycloserine Female Glycine Human Male N Methylaspartate Placebos Schizophrenia Amino Acids Blood Cycloserine *Therapeutic Use Glycine *Therapeutic Use Schizophrenia *Drug Therapy Schizophrenia Physiopathology

Description

To determine if glycine produces improvement in negative symptoms and D-cycloserine produces worsening in symptoms compared to placebo, patients will undergo a double blind study of d-cycloserine and glycine treatment added to clozapine. Clozapine is more effective for negative symptoms of schizophrenia than conventional neuroleptics, but the neurochemical actions contributing to this superior clinical efficacy remain unclear. Recent evidence points to a role for glutamatergic dysregulation in schizophrenia, as well as important differences between conventional agents and clozapine in effe...

Gender

All

Eligibility criteria

  • Inclusion Criteria:
  • Diagnosis of Schizophrenia
  • Score of 27 or greater on the Scale for the Assessment of Negative Symptoms (SANS)
  • Treatment with stable dose of clozapine for at least 4 weeks
  • Between 18 and 65 years old
  • Exclusion Criteria:
  • No other antipsychotic medications in oral for for at least 3 months or in depot form for 6 months
  • Current major depressive episode
  • Current substance abuse diagnosis

Attachments

readout_NCT00000372_2024-06-14.pdf

4.5 MB

NCT00000372_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Boston, Massachusetts, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Baseline, Week 8

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0